Risk for Foot Disease Modestly Lower With SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in T2DM

TUESDAY, Jan. 6, 2026-- For adults with type 2 diabetes mellitus (T2DM), new users of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) have a modestly lower risk for foot disease compared with glucagon-like peptide-1 receptor agonist (GLP-1...